𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Cysteine decrease following acute Levodopa intake in patients with Parkinson's disease

✍ Scribed by Thomas Müller; Siegfried Muhlack

Book ID
116774211
Publisher
Elsevier Science
Year
2012
Tongue
English
Weight
264 KB
Volume
521
Category
Article
ISSN
0304-3940

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Homocysteine levels after acute levodopa
Homocysteine levels after acute levodopa intake in patients with Parkinson's disease
✍ Thomas Müller; Wilfried Kuhn 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 84 KB

## Abstract Levodopa (L‐dopa) administered with a dopadecarboxylase inhibitor (DDI) increases homocysteine plasma levels. This may support the onset of atherosclerosis‐related disorders and neuropsychiatric complications in patients with Parkinson's disease (PD). This homocysteine elevation is cons

Cysteine elevation in levodopa-treated p
Cysteine elevation in levodopa-treated patients with Parkinson's disease
✍ Thomas Müller; Wilfried Kuhn 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 305 KB 👁 1 views

## Abstract Homocysteine, cysteine, and cysteinyl‐glycine are all metabolically interrelated. Levodopa/decarboxylase inhibitor (LD/DCI) administration increases total homocysteine (tHcy) plasma levels. Objectives were to investigate associations between LD/DCI intake, concentrations of tHcy, cystei

Hyperhomocysteinemia in levodopa-treated
Hyperhomocysteinemia in levodopa-treated patients with Parkinson's disease dementia
✍ Stefano Zoccolella; Claudia dell'Aquila; Giovanni Abruzzese; Angelo Antonini; Ub 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 78 KB

## Abstract Dementia is a frequent non‐motor feature of Parkinson's disease (PD). Elevated plasma homocysteine (Hcy) levels have been associated with both cognitive impairment and dementia. Increased Hcy levels have been observed in levodopa‐treated patients with PD. The objective of our study was